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Prolonged complement activation in mice. Because antibody
responses to the alternative complement pathway activator, cobra
venom factor, are T-dependent and B mice therefore do not
develop resistance to its action, it was possible to examine
whether renal injury occurs under circumstances of protracted
third-phase alternative pathway activation. After periods of up to
three months, no evidence from measurements of blood urea or
proteinuria or from examinations with light microscopy immuno-
fluorescence or electron microscopy was obtained to indicate a
directly nephrotoxic effect of this type of complement activation.
Activation prolongée du complement chez Ia souris. Du fait que
les réponses a l'activateur de Ia voie alterne du complement, le
venin de cobra, sont T-dépendantes et puisque les souris B, de ce
fait, ne développent pas de résistance a son action, ii a été possible
de rechercher la survenue de lesions rénales au cours d'une activa-
tion prolongée de Ia voie alterne; Aprés des délais atteignant
jusqua'à trois mois, aucun argument de néphrotoxicité n'a été tire
des mesures d'urCe sanguine et de protéinurie ou de l'étude en
microscopie photonique, d'immunofluorescence et électronique.
In this paper, we describe experiments designed to
determine whether persistent in vivo activation of
the alternative pathway of complement (C) directly
damages the kidney. Interest in this question has
arisen following the recognition that alternative path-
way activation in man is a feature of membranoproli-
ferative glomerulonephritis (MPGN), especially the
variety characterized by electron dense deposits in
glomerular and tubular basement membranes—
dense deposit disease [1, 2]. It has been established
that activation of the alternative pathway in this
disease is due to a serum factor, the so-called C3
nephritic factor (C3-NeF) [3, 4]. Some workers [5—
7] claim that this serum factor is related to a normal
serum protein involved in physiologic activation of
the alternative pathway, but others [8—121 have evi-
dence indicating it to be a distinctive IgG autoanti-
body. More recently, C3-NeF has been found to be
associated with a curious disorder of adipose tissue,
partial lipodystrophy, which itself is also sometimes
associated with MPGN [13, 141. It is now established
that C3-NeF causes complement activation by bind-
ing to and_stabilizing the alternative pathway en-
zymes (C3bBb and C3bB)a, i.e., prolonging their
half-lives [15,161.
So far, studies in experimental animals have failed
to provide evidence that systemic activation of com-
plement is nephrotoxic. Verroust, Wilson, and
Dixon [171 were unable to produce significant gb-
merular injury in rabbits by repeated injection of
particulate inulin or zymosan, activators of the alter-
native pathway. It is noteworthy, however, that the
degree of complement activation produced in this
way is much less than that which occurs in patients
with MPGN; furthermore, there are a number of
differences between the reaction mechanism of NeF,
which works efficiently in the fluid phase by a pro-
perdin-independent mechanism [16, 18, 19], acting
by making C3bBb resistant to its physiologic macti-
vators [20, 211 and the convertase generated by par-
ticulate polysaccharides which require properdin to
generate an efficient C3 convertase [22].
Another approach is the use of the complement-
activating factor in cobra venom. Cobra venom fac-
tor (CVF) causes complement activation by generat-
ing a C3 convertase, CVF-B, which has a long half-
life and, thus, simulates the state brought about by
NeF. In acute experiments [23, 24], there was no
evidence that CVF caused glomerular injury, but
examination of longer-term effects was not possible
owing to resistance due to antibody formation, which
usually develops within five to ten days. Pryjma and
aThe suffix "b" after a letter designating the complement protein is
applied to the larger fragment produced by cleavage; a bar over the
letter or letters indicates an enzymologically active form. C3bBb
thus consists of the cleavage products of C3, the third component
of complement, and the large fragment of factor B of the alterna-
tive pathway.
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Humphrey [25] have shown lately, however, that B
mice (neonatally thymectomized, lethally irradiated,
and bone-marrow-reconstituted mice) fail to make
antibodies to CVF, i.e., CVF is a T-dependent anti-
gen. Thus, the effects of protracted complement acti-
vation can be studied in such animals. Therefore, we
have repeated the experiments of Pryjma and Hum-
phrey to determine whether glomerular damage and,
in particular, changes resembling dense-deposit dis-
ease develop under these circumstances.
Methods
Animals. Three-to four-week-old CBA mice were
anesthetized i.p. with veterinary Nembutal diluted to
1:10 mi/tO g. The skin was divided between the
salivary glands, and the plane of connective tissue
around the trachea was entered and followed to the
sternum. About one-third of the sternum was split,
allowing removal of the thymus with a suction pi-
pette. The skin was approximated and pinched to-
gether with forceps. Two weeks later, the animals
were irradiated with 850 rad from a cobalt source and
injected with bone marrow. Marrow from two fe-
murs supplied sufficient cells for three animals. CVF
was started some three weeks later.
Cobra venom factor. CYF was purified from crude
Naja Naja venom (Sigma) by the method of Ballow
and Cochrane [261. The low-mol-wt active fraction
was stored at —70°C. The usual yield of CVF was 24
mg/g of crude venom, and the cobra venom factor
had anticomplementary activity, as defined by Bal-
low and Cochrane, of one unit in each five micro-
grams of protein.
Plasma C3 depletion. Cobra venom factor was
injected i.p. in four equal doses at eight-hour inter-
vals to initiate decomplementation, and thereafter, it
was injected as a single dose twice weekly. The dose
required to maintain plasma C3 levels at less than
10% of normal was usually four units per mouse (20
g of CYF). C3 concentrations were assayed by a
single radial-immunodiffusion method [27] using a
monospecific rabbit anti-mouse C3. The antiserum
was raised in rabbits by two injections of zymosan-
C3, washed 12 times in 2 M saline [28].
Proteinuria. At intervals, mice were placed in met-
abolic cages for 24-hr urine collection. Proteinuria
was estimated by a Biuret method [29].
Serum urea. Serum urea was measured using a
microurease method [30].
Histology. Kidney sections were prepared from
one kidney for light microscopy and immunofluores-
cence, as has been described previously [29]. Elec-
tron microscopy was performed on the other kidney.
The kidney was perfused in situ via the aorta with
ice-cold, freshly prepared 4% paraformaldehyde in
0.1 M phosphate buffer (pH, 7.2). Thereafter, the
tissue was postosmicated, dehydrated, and imbed-
ded in Epon resin.
Animal groups. There were four groups of ani-
mals: normal CBA animals injected with saline; thy-
mectomized (TXB) and irradiated CBA animals in-
jected with saline; thymectomized and irradiated
CBA animals injected with CVF; and normal CBA
animals injected with CVF.
After an initial settling-down period, when blood
was taken twice weekly for C3 estimation, comple-
ment levels were measured once weekly, before the
next injection of CVF. Thus, the C3 levels taken at
this time would be expected to be the highest during
that week.
Results
Fifteen thymectomized and irradiated mice (TXB
mice) were treated with CVF for periods between 72
and 100 days. Two animals died of unidentified pul-
monary infection, characterized by alveolar exuda-
tion. The other TXB and CVF-treated animals ap-
peared healthy, although they had a smaller weight
gain than control animals. The degree of complement
depletion is shown in Figure 1, most of the animals
having C3 values of less than 10% of normal before
the next injection. Only one of the 15 TXB animals
developed resistance to CVF; therefore, this animal
was excluded. None of the remainder had C3 con-
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Fig. 1. C3 levels as a percentage of pooled normal CBA mouse
serum. Closed circles denote thymectomized, irradiated, bone-
marrow-protected mice treated with cobnt venom factor. Dashed
line with open circles denote thymectomized, irradiated, bone
marrow protected mice injected with saline. Solid line with
squares denote normal CBA mice injected with saline. Open
squares with alternativedashes and dots denote normal CBA mice
injected with cobra venom factor (only until day 10).
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Fig. 2. An electron micrograph showing a normal capillary loop from a thymectomized, irradiated, bone-marrow-protected CBA mouse
after 100 days of decomplementation with cobra venom factor.
centrations greater than 25% at any measurement
during the experiment. Control CBA and TXB ani-
mals injected with normal saline had C3 values of 100
40% throughout the experiment. Normal CBA
mice injected with CVF developed resistance after
five to six days and became totally resistant at ten
days.
Serum urea and protein excretion. There was no
consistent rise in serum urea or in urine protein
excretion in any of the control experimental groups.
Histology. No changes were detected on light mi-
croscopy in the kidneys of the control, normal CBA
and TXB mice, or in the CYF-treated TXB mice.
Immunofluorescence. Minor deposits of mouse
IgG and C3 were found in kidneys from both groups
of control animals. TXB CVF-treated animals also
had minor deposits of immunoglobulin, but no C3
was detected.
Electron microscopy. Glomeruli from control nor-
mal CBA, TXB/CBA mice, and from CVF-treated
TXB mice were essentially normal (Fig. 2). A few
electron dense deposits were seen in some glomeruli
(Fig. 3), but there was no difference between CVF-
treated animals and animals given saline.
Discussion
We have been able to confirm the results of Pryjma
and Humphrey [15], that in "B mice" it is possible to
deplete complement (C) for prolonged periods by
repeated injections of CVF, and we have found that
after periods of up to three months these animals
show no evidence of renal disease: urinalysis, renal
function, light microscopy, immunofluorescence,
and ultrastructural microscopy were essentially nor-
mal. These results indicate that fluid-phase activation
of complement via the alternative pathway does not
per se cause glomerular damage. This is in keeping
with our studies of patients with partial lipodystro-
phy, a condition which is now recognized to be
associated with alternative pathway activation [13,
14]. Such patients usually have C3-NeF and hypo-
complementemia, but, though prone to develop mes-
angiocapillary nephritis of the dense-deposit variety,
they may not do so. Our findings are also consistent
with those of Verroust et al [171, who studied the
effects of repeated injection of zymosan and particu-
late inulin in rabbits, to which we have already
referred.
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Fig. 3. An extra-capillary 'hump." These presumed immune deposits were seen infrequently in cobra-venom-treated and control animals.
These clinical and experimental studies indicate
that factors other than alternative pathway activation
must be involved in the pathogenesis of MPGN,
although the clinical data strongly suggest that alter-
native pathway activation predisposes to its develop-
ment. We have considered the possibility that longer
periods of complement activation might be needed
before nephrotoxicity can be recognized; but in pa-
tients, electronmicroscopic evidence of recurrence
of dense deposit disease in renal allografts is fre-
quently observed within three months of transplant,
whereas no comparable damage occurred in this pe-
riod in our experiments. It is also noteworthy that
recurrence of dense deposit disease has been ob-
served lately in the absence of hypocomplementemia
[311.
We have previously suggested that the develop-
ment of nephritis in patients with alternative path-
way activation could be a result of complement defi-
ciency, by a mechanism similar to that operating in
patients with primary congenital deficiencies of the
complement system [131. An altogether different ex-
planation is that a product of complement activation
may be nephrotoxic in certain otherwise predisposed
individuals. Our present experiments do not help to
distinguish between these suggestions and the mech-
anisms responsible for the development of renal dis-
ease, and, for that matter, the disturbances in adi-
pose tissue remain uncertain.
It is interesting to note that the mortality in these
profoundly decomplemented and T-cell deficient ani-
mals was relatively low in a normal animal-house
environment. Presumably, complement-depleted
TXB mice still have defense mechanisms sufficient
for the elimination of many bacterial and other
infections.
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